Organon & Co.
$13.89-$0.02 (-0.1%)
Last close · Data as of Nov 20, 2026
- Market cap
- $3.5B
- P/E
- 18.8x
- EV / EBITDA
- 9.0x
- Revenue
- $6.2B
- Net margin
- 3.0%
- ROCE
- 11.7%
Price chart
Technical chartScreen technicals →+94.8% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +0.9%
- 3M
- +1.1%
- 6M
- +3.2%
- 1Y
- +94.8%
- 5Y
- -55.6%
52-week range
Day change -$0.02 (-0.1%) from $13.91 to $13.89 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in OGN, bought on each weekday since 2021.
News & filings
What Organon & Co. filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernDebt is more than ten times shareholders' equity.
Strengths (1)
- Return on equity of 24.9% against a peer median of 7.0%.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Read moreShow less
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
- Sector
- Healthcare
- Shares outstanding
- 259.7M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $3.5B
- P/E
- 18.8x
- P/B
- 4.7x
- EV / EBITDA
- 9.0x
- EV / Sales
- 1.9x
- P/S
- 0.6x
- 52-week high
- $13.92
- 52-week low
- $5.70
Profitability
- Operating margin
- 19.7%
- Net margin
- 3.0%
- EBITDA margin
- 20.8%
- ROE
- 24.9%
- ROCE
- 11.7%
- ROA
- 1.5%
- Asset turnover
- 0.48
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $6.2B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -2.9%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 0.2%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -78.4%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $384.0M
Solvency
- Current ratio
- 1.82
- Debt / Equity
- 11.49
- Debt / Assets
- 0.67
- CFO / Net profit
- 3.74
- Cash / Market cap
- 16.3%
Where the revenue went
Of every $100 of FY2025 revenue, $3 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $2.9B |
| Revenue | Gross profit | $3.3B |
| Gross profit | Research and development | $366.0M |
| Gross profit | Selling, general and administrative | $1.7B |
| Gross profit | Operating income | $1.2B |
| Operating income | Pretax income | $425.0M |
| Operating income | Interest and other expense | $801.0M |
| Pretax income | Tax and other | $238.0M |
| Pretax income | Net income | $187.0M |
Revenue and net profit
Revenue fell 2.9% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $6.2B | $917.0M |
| FY2023 | $6.3B | $1.0B |
| FY2024 | $6.4B | $864.0M |
| FY2025 | $6.2B | $187.0M |
Cash flows
FY2025: $700.0M from operations, $384.0M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $858.0M | $431.0M |
| FY2023 | $799.0M | $538.0M |
| FY2024 | $939.0M | $588.0M |
| FY2025 | $700.0M | $384.0M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $6.2B-2.9%1Y
- EBITDA
- $1.3B-19.6%1Y
- Net profit
- $187.0M-78.4%1Y
- Cash from operations
- $700.0M-25.5%1Y
- Free cash flow
- $384.0M-34.7%1Y
- Revenue CAGR, 3Y
- 0.2%
- Net profit CAGR, 3Y
- -41.1%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $6.2B | $1.3B | $187.0M | $384.0M | 24.9% | -2.9% | -78.4% |
Monthly returns
Month-by-month returns of OGN across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $12.9B |
| Current assets | $4.4B |
| Non-current assets | $8.5B |
| Liabilities | $12.1B |
| Current liabilities | $2.4B |
| Non-current liabilities | $9.7B |
| Equity | $752.0M |
| Paid-in capital | $167.0M |
| Retained earnings | $1.1B |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; OGN highlighted.
P/E against peers
OGN trades at 18.8x earnings against a peer median of 24.2x (a 22% discount).
Not shown (no positive earnings and no EV / Sales): Arcus Biosciences, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Organon & Co.OGNthis companyP/E ↓ discount | $3.5B | 18.8x | 4.7x | 24.9% | 9.0x |
| Waystar Holding Corp.WAY | $3.9B | 34.6x | 1.0x | 2.9% | 13.6x |
| Catalyst Pharmaceuticals, Inc.CPRX | $3.8B | 17.9x | 4.0x | 22.5% | 10.6x |
| Merit Medical Systems, Inc.MMSI | $3.8B | 29.3x | 2.4x | 8.1% | 12.5x |
| ACADIA Pharmaceuticals Inc.ACAD | $3.7B | 9.5x | 3.0x | 31.9% | 30.8x |
| ICU Medical, Inc.ICUI | $3.4B | 4607.1x | 1.6x | 0.0% | 14.7x |
| Concentra Group Holdings Parent, Inc.CON | $3.2B | 19.2x | 8.1x | 42.3% | 12.7x |
| Integer Holdings CorporationITGR | $3.1B | 30.6x | 1.8x | 5.9% | 15.2x |
| Arcus Biosciences, Inc.RCUS | $3.1B | -8.8x | 4.9x | -55.9% | -8.9x |
| Peer median | — | 24.2x | 2.7x | 7.0% | 13.1x |
Year-to-date ROI
OGN since 1 January, against earlier years.
Historical volatility
OGN's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 27.6% |
| FY2023 | 21.2% |
| FY2024 | 23.2% |
| FY2025 | 19.7% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $6.2B |
| Cost of revenueCost Of Revenue | $2.9B |
| Gross profitGross Profit | $3.3B |
| Operating expensesOperating Expense | $2.1B |
| Research and developmentResearch And Development | $366.0M |
| Selling, general and administrativeSelling General And Administration | $1.7B |
| Total expensesTotal Expenses | $5.0B |
| Operating incomeOperating Income | $1.2B |
| Interest and other | |
| Pretax incomePretax Income | $425.0M |
| TaxTax Provision | $238.0M |
| Net incomeNet Income | $187.0M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $12.9B |
| Current assetsCurrent Assets | $4.4B |
| Non-current assetsTotal Non Current Assets | $8.5B |
| LiabilitiesTotal Liabilities Net Minority Interest | $12.1B |
| Current liabilitiesCurrent Liabilities | $2.4B |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $9.7B |
| EquityTotal Equity Gross Minority Interest | $752.0M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $700.0M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $700.0M |
| Net income, continuing operationsNet Income From Continuing Operations | $187.0M |
| Depreciation and amortisationDepreciation And Amortization | $361.0M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $361.0M |
| Depreciation | $156.0M |
| Amortization cash flowAmortization Cash Flow | $205.0M |
| Amortization of intangiblesAmortization Of Intangibles | $205.0M |
| Stock-based compensationStock Based Compensation | $77.0M |
| Deferred taxDeferred Tax | $63.0M |
| Deferred income taxDeferred Income Tax | $63.0M |
| Operating gains and lossesOperating Gains Losses | -$94.0M |
| Net foreign currency exchange gain lossNet Foreign Currency Exchange Gain Loss | -$21.0M |
| Asset impairmentAsset Impairment Charge | $310.0M |
| Change in working capitalChange In Working Capital | -$247.0M |
| Other non-cash itemsOther Non Cash Items | $43.0M |
| Cash from discontinued operating activitiesCash From Discontinued Operating Activities | — |
| Investing cash flowInvesting Cash Flow | -$390.0M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$390.0M |
| Capital expenditureCapital Expenditure | -$316.0M |
| Capital expenditure (reported)Capital Expenditure Reported | -$162.0M |
| Sale of PP&ESale Of PPE | $1.0M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | $1.0M |
| AcquisitionsPurchase Of Business | -$75.0M |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$75.0M |
| Purchase of intangiblesPurchase Of Intangibles | -$154.0M |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | -$154.0M |
| Cash from discontinued investing activitiesCash From Discontinued Investing Activities | — |
| Financing cash flowFinancing Cash Flow | -$561.0M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$561.0M |
| Debt issuedIssuance Of Debt | $1.1B |
| Debt repaidRepayment Of Debt | -$1.5B |
| Net debt issuedNet Issuance Payments Of Debt | -$458.0M |
| Short-term debt issuedShort Term Debt Issuance | — |
| Short-term debt repaidShort Term Debt Payments | — |
| Net short-term debt issuedNet Short Term Debt Issuance | — |
| Long-term debt issuedLong Term Debt Issuance | $1.1B |
| Long-term debt repaidLong Term Debt Payments | -$1.5B |
| Net long-term debt issuedNet Long Term Debt Issuance | -$458.0M |
| Dividends paidCash Dividends Paid | -$88.0M |
| Common dividends paidCommon Stock Dividend Paid | -$88.0M |
| Other financing chargesNet Other Financing Charges | -$15.0M |
| Cash from discontinued financing activitiesCash From Discontinued Financing Activities | — |
| Change in cashChanges In Cash | -$251.0M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 15,000.0% |
| Other cash adjustment outside change in cashOther Cash Adjustment Outside Changein Cash | — |
| Cash at the start of the yearBeginning Cash Position | $675.0M |
| Cash at the end of the yearEnd Cash Position | $574.0M |
| Free cash flowFree Cash Flow | $384.0M |
Learn while you research
Academy chapters picked for Organon & Co. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Leverage RatiosDebt/Equity of 11.49 is elevated, understand what that means for solvency.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read